

Statistical Profile

1 April 2018 to 31 March 2021



Key Met acceptable

Southern Unit Consolidated 3 yr Performance Summary: 1st April 2018 to 31st March 2021												
KPI	Standard		KC62	Activity Data	1st Apri	o 31St IVI	ce National Standards					
KFI	The Percentage of		Source	Invited	18/19 19/20 17,187 13,425		20/21 14.222	18-21 44,834	National Standards			
Uptake	Eligible Women Who Attend for	Overall	Table A-C2	Screened	13,301	10,254	10,544	34,099	Minimum - 709/			
	Screening		Age 50-70	Uptake Rate (%)	77	76	74	76	Minimum <u>></u> 70% Achievable >80%			
Uptake	The Percentage of Eligible Women	Prevalent Screen	Table A Age 45-52	Invited Screened	2,933 2,152	2,346 1,724	2,493 1,799	7,772 5,675	Non KPI Measure of			
	Who Attend for The Percentage of	Incident	Table C1	Uptake Rate (%) Invited	73.37 11,330	73.49 8,790	72.16 9,251	73.02 29,371	Performance (prevalent was age 50-52			
Uptake	Eligible Women Who Attend for	Screen	Age 50-70	Screened Uptake Rate (%)	10,229 90.28	7,910 89.99	8,107 87.63	26,246 89.36	Incident was age 53-70)			
		Prevalent	Table A	Screened	2,152	1,724	1,799	5,675 442	Prevalent age cohort change: 45-52 from April 2017			
Referral to Assessment	The Percentage of	Screen	Age 45-52		8.13	7.95	7.23	7.79	Minimum <10%			
	Women Referred to Assessment			(%) Screened	10,229	7,910	8,107	26,246	Achievable <7% Incident age cohort change:			
		Incident Screen	Table C1 Age 50-70	Assessed Referred to Assessment Rate	410	318	317	1,045	50-70 from April 2017 Minimum <7%			
				(%) Screened	4.01 13,466	4.02 10,409	3.91 10,645	3.98	Achievable <5%			
Short Term Recall	The Percentage of Women Placed on Short Term Recall	Overall	Table T Age 50-70	Short Term Recall	0	1	0	1	Minimum 0.050/			
Recail				Short Term Recall Rate (%)	0.00	0.01	0.00	0.00	Minimum <0.25% Achievable <0.12%			
	The Rate of Invasive	Prevalent	Table A	Screened Invasive Cancers	2,152 7	1,724 10	1,799 17	5,675 34	Not a KPI from April 2017 (was age 50-52 at			
Invasive	Cancers Detected in	Screen	Age 45-52	Invasive Cancer Detection Rate (per 1,000)	3.25	5.80	9.45	5.99	Minimum <u>></u> 2.7/1000 Achievable <u>></u> 3.6/1000)			
Cancer Detection	Eligible Women Invited and Screened	Incident	Table C4	Screened	10,229	7,910	8,107	26,246	Not a KPI from April 2017			
		Screen	Table C1 Age 50-70	Invasive Cancers Invasive Cancer Detection	5.96	7.59	68 8.39	189 7.20	(was age 53-70 at Minimum <u>></u> 3.1/1000			
				Rate (per 1,000) Screened	2.256	1.800	1.919	5.975	Achievable >4.2/1000) Prevalent age cohort change:			
	The Rate of Non- Invasive Cancers Detected in Eligible Women Invited and Screened	Prevalent Screen Incident	Table A Age 45-70	Non/Micro Invasive Cancers Non-Invasive Cancer	3	4	3	10	45-70 from April 2017			
Non-Invasive Cancer				Detection Rate (per 1,000)	1.33	2.22	1.56	1.67	Minimum >0.5/1000 Incident age cohort change:			
Detection			Table C1	Non/Micro Invasive Cancers	10,229 8	7,910 7	8,107 14	26,246 29	50-70 from April 2017			
	Goldanda	Screen	Age 50-70	Non-Invasive Cancer Detection Rate (per 1,000)	0.78	0.88	1.73	1.10	Minimum <u>></u> 0.6/1000			
SDR	Standardised	Prevalent & Incident	Table A-C1	Observed Expected	74 52.71	72 40.76	92 42.34	238 135.81	Not a KPI from April 2017			
	Detection Ratio	Screen	Age 45-70	SDR	1.40	1.77	2.17	1.75	(was age 50-70) New KPI from April 2017			
SDR	Standardised	Prevalent & Incident	Table A-C1	Observed Expected	43 28.99	46 22.42	51 23.29	140 74.69	(was aged 50-70)			
<15mm	Detection Ratio	Screen	Age 45-70	SDR	1.48	2.05	2.19	1.87	Minimum >1.0 Achievable >1.4			
	Standardised Detection Ratio Standardised Detection Ratio	Prevalent Screen Prevalent	Table	Observed Expected	13 11.08	12 8.31	24 9.02	49 28.40	New KPI from April 2017 (was aged 50-70)			
SDR			A + B Age 45-70	SDR	1.17	1.44	2.66	1.73	Minimum >1.0			
SDR			Table	Observed	7	8	11	26	Achievable >1.4 Non KPI Measure of			
<15mm		Screen	A + B Age 45-70	Expected SDR	6.09 1.15	4.57 1.75	4.96 2.22	15.62 1.66	Performance			
	Standardised Detection Ratio	Incident Screen Incident	Table C1 Age 50-70	Observed Expected	61 41.64	60 32.45	68 33.32	189 107.41	New KPI from April 2017			
SDR				SDR	1.47	1.85	2.04	1.76	Minimum >1.0			
SDR				Observed	36	38	40	114	Achievable >1.4 Non KPI Measure of			
<15mm	Detection Ratio	Screen	Age 50-70	Expected SDR	22.90 1.57	17.85 2.13	18.33 2.18	59.07 1.93	Performance			
SDR	Standardised	Prevalent	Table A + B Age	Observed Expected	8 7.91	10	17 6.46	35 20.67				
ODIC	Standardised Detection Ratio	Screen	45-52	SDR	1.01	1.59	2.63	1.69	Non KPI Measure of			
SDR <15mm		Prevalent Screen	Table A + B Age	Observed Expected	5 4.35	6 3.47	9 3.55	20 11.37	Performance			
V10111111	The Rate of Invasive Cancers <15mm Detected in Eligible Women Invited and Screened The Percentage of Women who have a	Prevalent Screen	45-52 Table A Age 45-52 Table C1	SDR Screened	1.15 2.152	1.73 1.724	2.53 1.799	1.76 5.675	Not a KPI from April 2017			
Small				Invasive Cancers <15mm Small Invasive Cancer	4	6	9	19	(was age 50-52 at Minimum >2.0/1000			
Invasive				Detection Rate (per 1,000)	1.86	3.48	5.00	3.35	Achievable >2.8/1000)			
Cancer Detection		Incident		Screened Invasive Cancers <15mm	10,229 36	7,910 38	8,107 40	26,246 114	Not a KPI from April 2017 (was age 53-70 at			
		Screen	Age 50-70	Small Invasive Cancer Detection Rate (per 1,000)	3.52	4.80	4.93	4.34	Minimum <u>></u> 2.3/1000 Achievable <u>></u> 3.1/1000)			
		Invasiva		Referred for Cytology/Core	86	74 74	98 98	258	<u> </u>			
Non-	Non-Operative Diagnosis of Cancer by Cytology or Needle Histology after a Maximum of 2 Visits	Invasive Cancers	Table T Age 50-70	Invasive cancers Invasive Non-operative	86 100.00	100.00	100.00	258 100.00	Minimum >90%			
Operative		Non- Invasive Cancers		diagnosis Rate (%) Referred for Cytology/Core	15	11	18	44	Achievable >95%			
Diagnosis				Non-Invasive Cancers DCIS Non-operative	14	11	18	43	Minimum >85%			
				diagnosis rate (%)	93.33	100.00	100.00	97.73	Achievable >90% Prevalent age cohort change:			
	The Rate of Benign	Prevalent Screen Incident	Table A Age 45-52 Table C1 Age 50-70	Screened Benign Biopsies	2,152 1	1,724 0	1,799 0	5,675 1	45-52 from April 2017			
Benign				Benign Biopsy Rate (per 1,000)	0.46	0.00	0.00	0.18	Minimum <1.5/1000 Achievable <1.0/1000			
Biopsy	Biopsies			Screened Benign Biopsies	10,229	7,910 2	8,107 1	26,246 6	Incident age cohort change: 50-70 from April 2017			
		Screen		Benign Biopsy Rate (per	0.29	0.25	0.12	0.23	Minimum <1.0/1000			
KPI	Q+e	ndard		1,000) Activity Data		Local Per	formance		Achievable <0.75/1000 National Standards			
	The Percentage of		ose Eim	Previously Screened	18/19 12,563	19/20 9,741	20/21 10,276	18-21 32,580	otaniaa as			
Screen Round	Offered Appointmen	t is Within 36		FOA <36m	12,530	9,728	581	22,839	Minimum ≥90%			
Length	Their Pre	vious Screen		FOA <36m (%)	100	100	6	70	Achievable 100% Minimum standard change			
Waiting Time	The Percentage of Women Who are Se Their Result Within 2 Weeks			Screened Result <2 weeks	13,695 13,692	10,657 10,655	10,416 10,412	34,768 34,759	from April 2017			
for Results	Their Result	vvitnin 2 Wee	eks	Result <2 weeks (%)	100.0	100.0	100.0	100.0	Minimum <u>></u> 95% Achievable 100%			
Technical		=		Screened Tech recalls/repeats	14,413 366	11,129 240	11,176 355	36,718 961				
Recall/ Repeat	The Number of F	kepeat Exami	nations	Tech recalls/repeats (%)	2.54	2.16	3.18	2.62	Minimum <3%			
Waiting Time	Percentage of Women who are Offered			Offered Assessment	715	562	516	1,793	Achievable <2% Minimum standard change			
for	Appointment for Ass of Attendance for the	essment with	in 3 Weeks	Offered <3 weeks	714	562	516	1,792	from April 2017 Minimum >98%			
Assessment Waiting Time	Percentage of W			Offered <3 weeks (%) Assessed	99.9 710	100.0 559	100.0 516	99.9 1,785	Achievable 100%			
for Assessment	Assessment Centre	within Three	Weeks of					1,680	Non KPI Measure of Performance			
Manuscassi	Attendance for the S	oreening Ma	mmogram	ASSESSED SO WEEKS (%)	J4.0	31.4	30.I	34. I				

OBJECTIVE	Northern Ireland			BHSCT			NHSCT			SHSCT			WHSCT			Acceptable	Achieveable
	18/19	19/20	20/21	18/19	19/20	20/21	18/19	19/20	20/21	18/19	19/20	20/21	18/19	19/20	20/21		
Uptake Rate %																	
Prevalent	73.66	72.05	70.84	71.47	69.56	68.05	77.94	73.41	74.38	73.37	73.49	72.16	74.36	74.09	71.17		
Incident	89.90	89.21	85.76	88.75	89.52	84.88	91.13	87.71	86.39	90.28	89.99	87.63	90.56	89.80	84.98	≥70%	<u>></u> 80%
Overall	76.89	76.01	72.18	74.14	74.39	68.63	80.40	76.81	75.83	77.39	76.38	74.14	78.54	78.10	73.09	-	_
Technical Recall/Repeat %	2.65	2.39	2.93	2.92	2.54	2.95	2.77	2.24	2.73	2.54	2.16	3.18	2.82	1.87	2.87	<3%	<2%
Percentage Assessed %																	
Prevalent	5.98	5.53	5.06	6.54	5.71	4.91	5.59	4.11	4.14	8.13	7.95	7.23	3.58	4.64	4.33	<10%	<7
Incident	2.54	2.52	2.27	2.01	2.14	1.73	2.15	1.93	1.94	4.01	4.02	3.91	2.37	2.74	2.01		<7 <5
Early Recall %	0.03	0.01	0.01	0.02	0.00	0.01	0.05	0.01	0.03	0.00	0.01	0.00	0.05	0.02	0.02	<7% <0.25%	<0.12%
Benign Biopsy Rate	0.03	0.01	0.01	0.02	0.00	0.01	0.03	0.01	0.03	0.00	0.01	0.00	0.03	0.02	0.02	<0.25%	<0.1276
Prevalent	1.00	0.65	0.32	0.28	0.00	0.00	3.42	2.14	0.00	0.46	0.00	0.00	0.80	0.59	1.47	<1.5/1000	<1.0/1000
Incident	0.31	0.25	0.24	0.16	0.05	0.07	0.36	0.35	0.32	0.29	0.25	0.12	0.52	0.54	0.54	<1.0/1000	<0.75/1000
DCIS Cancer Rate	0.40	4.50	0.00	0.44	0.00	4.05	0.00	0.40	0.40	4.00	0.00	4.50	0.40	0.07	4.07	/	
Prevalent	2.48	1.56	2.03	2.11	0.28	1.65	3.80	2.48	0.46	1.33	2.22	1.56	3.10	2.27	4.67	>05./1000	N/A
Incident	1.13	1.29	1.30	0.87	1.45	1.15	1.68	1.41	0.85	0.78	0.88	1.73	1.47	1.19	1.61	>=0.6/1000	N/A
Invasive Cancer Rate																	
Prevalent	3.7	4.9	5.9	3.3	4.9	3.8	5.1	4.3	4.3	3.3	5.8	9.4	3.6	4.8	7.9	>=2.70/1000	>=3.6/1000
Incident	5.7	6.5	6.1	4.9	6.1	5.7	5.5	6.0	5.3	6.0	7.6	8.4	7.0	7.0	5.7	>=3.10/1000	>=4.2/1000
Small Invasive Cancer Rate																	
Prevalent	1.7	1.6	2.5	1.4	1.7	0.9	1.7	0.9	2.9	1.9	3.5	5.0	2.0	0.6	2.5	<u>></u> 2.0	<u>></u> 2.8
Incident	3.1	3.5	3.3	2.5	3.3	2.7	3.2	2.6	3.4	3.5	4.8	4.9	3.5	3.8	2.7	<u>></u> 2.3	<u>></u> 3.1
Invasive Pre-operative Diagnosis Rate % Non invasive Pre- operative Diagnosis Rate	100.00	98.68	99.73	100.00	99.29	99.16	100.00	95.24	100.00	100.00	100.00	100.00	100.00	100.00	100.00	<u>≥</u> 95%	N/A
%	92.22	96.43	94.87	100.00	96.77	92.59	90.00	95.83	80.00	93.33	100.00	100.00	84.62	94.44	100.00	<u>≥</u> 95%	N/A
Roundlength ≤ 36 months	96.4	99.3	12.3	97.8	92.8	7.7	97.3	98.9	12.9	99.7	99.9	5.7	98.5	98.7	24.9	>90%	100%
Screen to Results	99.7	94.9	99.9	99.8	99.8	99.8	99.9	79.8	99.9	100.0	100.0	100.0	99.3	99.3	100.0	>95%	100%
(% ≤ 2 weeks)																	
Screen to Assessment (% ≤ 3 weeks) Date of offered																	
appointment Date of attended	99.0	99.2	99.4	98.5	98.0	98.2	98.2	100.0	100.0	99.9	100.0	100.0	99.1	99.7	99.7	>98%	100%
appointment	99.0	99.2	99.4	93.3	90.2	91.6	94.7	92.2	94.2	94.8	91.4	96.1	89.1	96.1	98.1	N/A	N/A